DDInter1008 DDInter1228
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) causes {v} (Side Effect) Mediastinal disorder
Mediastinal disorder {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) causes {v} (Side Effect) Mediastinal disorder
Mediastinal disorder {u} (Side Effect) is caused by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erlotinib
Erlotinib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Sunitinib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Ketoconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Mipomersen
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Mipomersen